Post-graft hematopoiesis is characterized by long-term quantitative deficiency in marrow progenitor cells in both autologous and allogenic settings. In order to evaluate the function of post-graft progenitor cells, the proliferative capacity of marrow CD34
Over the past 15 years, high-dose therapy has been widely used in onco-hematology to improve the efficacy of antitumor treatments. The high myelotoxicity of such regimens requires hematopoietic rescue by transplantation of allogeneic, syngeneic or autologous progenitor and stem cells. To ensure full and stable hematopoietic reconstitution, these grafts must contain sufficient amounts of precursor and progenitor cells responsible for early engraftment and primitive stem cells for late engraftment.
1,2 Normalization of peripheral blood cell (PBC) counts is usually considered to estimate successful hematopoietic engraftment but this criterion does not really reflect full hematopoietic reconstitution. Indeed, as shown after allogeneic bone marrow transplantation (BMT), 3 we have reported a decrease in marrow hematopoietic progenitor cell (HPC) frequency for up to 4 years after autologous BMT (ABMT) 4 whereas most of the patients studied normalized PBC counts within 4-6 weeks. A long-lasting impairment of the hematopoietic system could lead to the emergence of secondary hemopathies such as myelodysplastic syndrome or acute leukemia whose actuarial risk at 10 years has been estimated to be above 10% in several reports. [5] [6] [7] [8] Although we noted that post-graft deficiency of HPC from the mononuclear cell (MNC) fraction mainly involved the erythroid lineage, 4 it could not be attributed to an abnormal response of erythroid progenitor cells to stem cell factor (SCF) that increased their clonogenicity as well as erythroid colony size. 9 However, using a Dexter-type long-term marrow culture (LTMC) system, 10 we found a decrease in CFU-GM production for up to 1 year after ABMT. 11, 12 This correlated with low initial counts of erythroid progenitor cells and suggested abnormal proliferative capacity at the primitive cell level. 11 The aim of this study was to evaluate the proliferative capacity of immature HPC after ABMT in response to early-acting growth factors (GF) using a short-term stroma-free liquid culture system. Production of CFU-GM and BFU-E obtained from selected CD34 ϩ marrow cells was assessed after culture in serum-deprived medium for 7 days with the combination of stem cell factor (SCF), IL-3 and IL-1␤.
Materials and methods

Patients
Marrow cells were obtained from 10 patients (five males and five females) with a median age of 42 years (range 31-50 years) 6 months after ABMT for non-Hodgkin's lymphoma (NHL) (Department of Medical Oncology and Blood Diseases, Bretonneau Hospital, University Hospital of Tours, France). One patient was at stage II at diagnosis, three patients at stage III and five at stage IV, including five patients with marrow involvement. Six patients were autografted in first remission and four in second remission. The results for transplanted patients were compared to those for 10 patients with lymphoid malignancies (eight NHL, one Hodgkin's disease and one acute lymphoblastic leukemia) before autologous transplantation (studied at the time of graft collection) and for 10 control patients undergoing cardiac surgery without any hematologic disorder (Department of Cardiac Surgery, Trousseau Hospital, University Hospital of Tours, France). Informed consent was obtained from all patients.
Transplantation procedure
Autologous marrow grafts were collected in continuous remission state by iliac crest puncture, concentrated with a semi-continuous flow cell separator (Haemonetics 30 S) and purged in vitro of B cells by an immunological procedure in eight cases (MaxSep; Baxter, Munich, Germany). Grafts were immediately frozen in bags using a Nicool ST 316 programmed freezing unit (CFPO, Sassenage, France) and stored in liquid nitrogen at Ϫ196°C. As pre-graft conditioning regimen, the patients received fractionated total body irradiation at 10 Gy (TBI) for 4 days followed by 60 mg/kg/day cyclophosphamide for 2 days, except for two patients who received BEAM regimen consisting of 300 mg/m 2 BCNU for 1 day, 200 mg/m 2 /day etoposide (VP-16) and 200 mg/m 2 /day cytosine arabinoside (Ara-C) for 4 days followed by high-dose melphalan at 140 mg/m 2 for 1 day. At the time of transplantation marrow bags were quickly thawed in a 37°C waterbath at the bedside and were immediately infused intravenously. All the patients received recombinant human hematopoietic GF by the intravenous route at 5 g/kg/day after transplantation from day 0 and until neutrophil counts exceeded 1 × 10 9 /1 for 3 consecutive days. RhuG-CSF (Amgen, Thousand Oaks, CA, USA) was infused in nine cases and rhuGM-CSF (Schering-Plough, Madison, NJ, USA) in the other case.
CD34
+ cell selection Marrow samples were collected in tubes containing preservative-free heparin. Bone marrow MNC were separated by sedimentation through a Ficoll-Hypaque gradient (d = 1.077, Lymphoprep; Nycomed, Oslo, Norway). Cells bearing the CD34 antigen were isolated from MNC by positive selection using a direct immunoadherence panning technique, as previously described. 13 Briefly, mature cells were initially removed from the MNC preparation by adherence to T25 flasks coated with soybean agglutinin (SBA) for 60 min. The CD34 ϩ cell fraction was then positively selected from SBA ϩ cells on similar T25 flasks coated with an anti-CD34 antibody (ICH3). After 60 min incubation CD34
Ϫ cells were removed and CD34 ϩ (ICH3 ϩ ) cells easily detached after overnight incubation at 37°C in McCoy's 5A medium (Boehringer-Mannheim, Meylan, France) supplemented with 15% fetal calf serum (FCS) (Gibco/BRL, Cergy-Pontoise, France).
Immunophenotyping and flow cytometry
Small aliquots of selected cells were incubated for 30 min at 4°C with an anti-CD34 monoclonal antibody (mAb) (HPCA-2; Becton Dickinson, Mountain View, CA, USA) conjugated with fluorescein isothiocyanate (FITC) or with phycoerythrin (PE). The percentage of positive cells was assessed by flow cytometry with an argon-ion laser tuned at 488 nm (Epics Profile II; Coultronics, Miami, FL, USA) compared to an isotype-matched negative control antibody. Co-expression of CD38 and c-kit antigens on CD34 ϩ cells was determined using mAb in two-color flow cytometric experiments, where FITC-conjugated Leu-17 (anti-CD38; Caltag, Burlingame, CA, USA) was used together with PEconjugated HPCA-2 and PE-conjugated anti-c-kit (anti-CD117, Immunotech, Marseille, France) with FITCconjugated HPCA-2.
Short-term liquid culture of selected cells
CD34
ϩ cells were cultured in polystyrene U-bottom tubes for 7 days at 37°C with 5% CO 2 at 1 × 10 4 /ml in serumdeprived medium consisting of Iscove's medium (Boehringer-Mannheim) with 7.8 g/ml cholesterol (Sigma, St Quentin-en-Yvelines, France), 30 g/ml L-␣ phosphatidyl choline (Sigma), 0.3 mg/ml transferrin (Sigma), 0.25 U/ml human insulin, 10 Ϫ4 m ␤-mercaptoethanol (␤ME) (Sigma), 1% deionized bovine serum albumin (BSA) (Sigma), 0.1 mm pyruvate, 2 mm l-glutamine, 1% penicillin-streptomycin and 0.25 g/ml amphotericin B. Culture medium was supplemented on day 0 with 10 ng/ml SCF (kindly provided by Amgen), 10 ng/ml IL-3 (Boehringer-Mannheim) and 50 U/ml IL-1␤ (PeproTech, Rocky Hill, NJ, USA).
Clonogenic assays
Unselected MNC and CD34-selected cells were assayed in semi-solid medium for CFU-GM and BFU-E before and after 7-day liquid culture. Cells were plated in triplicate 35 mm-Petri dishes (Nunc, Oslo, Denmark) at 2 × 10 4 /ml for unselected cells and at 500/ml and 1000/ml for selected cells on day 0 and day 7 of liquid culture, respectively. Cultures were performed in Iscove's medium supplemented with 1% methylcellulose (Sigma), 30% FCS, 10 Ϫ4 m ␤ME, 1% deionized BSA, 0.1 mm pyruvate, 2 mm l-glutamine, 1% penicillin-streptomycin and 0.25 g/ml amphotericin B. Recombinant human GF were used, including G-CSF (Amgen), GM-CSF (Schering-Plough), IL-3 and SCF (Amgen), each factor at 10 ng/ml for CFU-GM assay with the addition of 3 U/ml Epo (Boehringer-Mannheim) for BFU-E assay. Cells were incubated at 37°C in a humidified 5% CO 2 atmosphere and plates scored in situ by inverted microscopy on day 14 for CFU-GM (aggregates Ͼ50 nonhemoglobinized cells) and BFU-E (aggregates Ͼ200 hemoglobinized cells).
Statistical analysis
The values presented for each group are means ± s.e.m. The non-parametric Mann-Whitney U test was used for comparison of value distributions between groups and the Wilcoxon's t-test for evaluation of cell increase in each group.
Results
Immunophenotype of selected cells
The percentage of CD34 ϩ cells (mean Ϯ s.e.m.) within the selected cell fraction was not different in pre-graft (82.2 ± 2.3%) and post-graft patients (63.5 ± 7.0%) compared to controls (79.8 ± 3.6%) (Figure 1) . However, the percentage was slightly lower in post-graft patients compared to pregraft patients (P = 0.045). Among the selected CD34 ϩ cells, the primitive cell subset lacking the CD38 antigen (CD34 ϩ CD38 Ϫ cell population) was significantly decreased in both post-graft (P = 0.014) and pre-graft patients (P = 0.034) compared to controls. However, the proportion of cells that expressed the c-kit receptor was similar in all three groups, representing more than 50% of cells.
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Clonogenic efficiency of unselected and selected cells
Clonogenic efficiency of unselected MNC for CFU-GM and BFU-E was decreased only in post-graft patients (Figure 2 ), compared to pre-graft patients (P = 0.002 and P = 0.003, respectively) and controls (P = 0.0005 and P = 0.0002, respectively). After selection, clonogenic efficiency of CD34 ϩ cells (from selected cells corrected for CD34 ϩ cell purity) for CFU-GM was similar in all three groups, while it remained significantly lower for BFU-E in post-graft patients than in controls (P = 0.015). Clonogenic efficiency before and after cell selection. Cells were plated in 1 ml Petri dishes at 2 × 10 4 /ml before selection (MNC) and at 500/ml after selection (CD34 ϩ cells). Cultures were performed in Iscove's medium with 1% methylcellulose and 30% FCS supplemented with G-CSF, GM-CSF, IL-3 and SCF (each at 10 ng/ml) for CFU-GM assay with the addition of 3 U/ml Epo for BFU-E assay. Cells were incubated at 37°C in a humidified 5% CO 2 atmosphere and plates scored on day 14 for colony growth. Columns represent means and are in white for controls (n = 10), grey for pre-graft patients (n = 10), and black for post-graft patients (n = 10). Bars represent the s.e.m. *Significantly different from both control and pre-graft values.
#
Significantly different from control values.
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Expansion of nucleated cells and progenitor cells from selected cells after 7-day liquid culture
Seven-day culture of CD34 ϩ cells with a combination of SCF, IL-3 and IL-1␤ induced significant expansion of total nucleated cells in all three groups, with mean (Ϯ s.e.m.) values of 443 ± 86%, 218 ± 61% and 495 ± 82% in pregraft, post-graft patients and controls, respectively. This was also found for total CFU in pre-graft patients (255 ± 27%) and controls (246 ± 23%) but not in post-graft patients (147 ± 28%). CFU-GM were significantly expanded in pre-graft, post-graft and control groups (296 ± 40%, 169 ± 30% and 240 ± 33%, respectively) while this was observed for BFU-E only in controls (349 ± 82%; P = 0.009) and not in pre-graft (220 ± 82%) or post-graft (61 ± 24%) patients. Post-graft patients displayed significant decrease in expansion yields for nucleated cells (P = 0.016), total CFU (P = 0.023), CFU-GM (P = 0.023) and BFU-E (P = 0.048) compared to pre-graft patients, and for nucleated cells (P = 0.016), total CFU (P = 0.019) and BFU-E (P = 0.002) compared to controls. Thus, absolute numbers of HPC produced after liquid culture (Figure 3 ) in post-graft patients were lower than in controls and pre-graft patients for CFU-GM (P = 0.028 and P = 0.028) and especially for BFU-E (P = 0.0001 and P = 0.008) whose levels tended to be even lower than pre-culture levels (P = 0.058).
Discussion
This study shows that the quantitative deficiency in clonogenic HPC from mononuclear and CD34 ϩ cells observed after ABMT is associated with impaired capacity of CD34 ϩ cells to proliferate in response to early-acting GF. This post-graft abnormality, which involves erythroid progenitor cells and/or commitment towards erythroid lineage from a more immature stage (pre-CFU), is associated with depletion of the immature CD34 ϩ CD38 Ϫ cell population. ϩ cells were cultured for 7 days at 37°C with 5% CO 2 at 1 × 10 4 /ml in liquid serum-deprived medium. Culture medium was supplemented on day 0 with 10 ng/ml SCF, 10 ng/ml IL-3 and 50 U/ml IL-1␤. CFU-GM-and BFU-E-derived colonies were assessed before and after liquid culture as described in Figure 2 . Columns represent means and are in white for controls (n = 10), grey for pre-graft patients (n = 10), and black for post-graft patients (n = 10). Bars represent the s.e.m. *Significantly different from both control and pre-graft values.
# Significantly different from control values.
These findings are consistent with long-term qualitative and/or quantitative damage of the primitive cell compartment after ABMT.
Post-graft HPC deficiency was observed in the MNC fraction, as already demonstrated over a period of months after allogenic 3 and autologous 4 transplantation. The origin of post-graft hematopoietic impairment is considered to be the result of multiple factors related to the patient (such as diagnosis and previous antitumoral treatments) and to the transplantation procedure itself (such as quality and quantity of HPC transplanted and conditioning regimen). In our study, this deficiency was also present in the CD34 ϩ cell population, particularly for BFU-E (significance was not reached for CFU-GM), as previously reported by others after transplantation with peripheral blood 14 and with allogeneic bone marrow 15 grafts. The decreased clonogenicity of post-graft CD34 ϩ cells cannot be explained by the slightly lower CD34 ϩ cell percentage obtained after selection since all results were corrected for CD34 ϩ purity. Lower quality of CD34 selection of post-graft MNC is probably the consequence of a defect in CD34 antigen expression irrespective of the selection technique, as recently shown by our group using an immunomagnetic procedure. 12 HPC deficiency is most probably due to depletion of clonogenic cells rather than to abnormal recruitment by early-acting GF of such cells, shown to respond normally to SCF. 9 In addition, the CD34 ϩ CD38 Ϫ cell subpopulation, known to be enriched in hematopoietic stem cells, 16, 17 was clearly found to be depleted after transplantation in our study. The fact that this decrease was already present during the pre-graft period probably reflects toxicity of prior chemotherapy which has been shown to influence post-graft reconstitution of the primitive cell compartment in experimental models. 18 As in our study, deficiency in the primitive progenitor cell compartment has also been recently reported in patients before autologous transplantation for NHL with regard to frequencies of CD34 ϩ CD38 Ϫ cells, cobblestone area-forming cells (CAFC) 19 or LTC-IC. 20 It is not surprising to find that the primitive cell defect persists after transplantation but, as reported after allogeneic transplantation, [21] [22] [23] it appears much more pronounced. Our findings of decreased post-graft percentages of CD34 ϩ CD38
Ϫ cells in the autologous setting (ie irrespective of any immune reaction or immunosuppressive therapy) emphasize the predominant role of the transplantation procedure (particularly high-dose therapy) and/or previous chemotherapy in stem cell damage. This is in accordance with results from LTC-IC assays 12 reported elsewhere by our group and those reported by Novitzky et al 24 concerning stroma-adherent primitive clonogenic precursors.
The decreased capacity of CD34 ϩ cells to proliferate in response to early-acting GF shown in our study suggests a qualitative abnormality involving the primitive cell compartment several months after ABMT, as indicated by the decreased production of CFU-GM in LTMC we have previously reported. 11 Our findings are in agreement with those of Soligo et al, 20 who also reported a defective proliferative response of CFU-GM from MNC to a combination of SCF, IL-3, IL-6 and GM-CSF. There is some evidence of impaired proliferative potential of hematopoietic cells after transplantation. Limitation of stem cell self-renewal has been clearly shown in mouse models after serial transplantations, 25 transplantation in old animals 26 and infusion of limited numbers of bone marrow cells, 27 as occurs for clinical transplantation in humans. These cells would be predominantly triggered towards differentiation at the expense of their self-renewal capacity with an increased proportion of cycling cells. 3 Lansdorp et al 28 reported that the proliferative potential of primitive cells is inversely correlated with the differentiation stage of cell ontogeny and is associated with telomere length. 29 Thus an intrinsic timetable model of hematopoiesis has been proposed in which self-renewal properties of stem cells are limited to less than 100 cell divisions. In addition, it has been shown that primitive progenitor cells lose their telomere DNA when they are induced to proliferate. 29 This could explain telomere shortening after transplantation in humans using either allogeneic 30 or autologous 31 grafts that could in turn compromise the proliferative potential of primitive cells and then their capacity for long-term hematopoietic reconstitution. One possible additional factor accounting for post-graft primitive cell impairment may be a defect of stromal cells, particularly in their ability to produce early-acting GF 32, 33 or to support the proliferation of primitive progenitor cells. 24, 32, 34 However a post-graft defect in self-renewal of primitive cells has been shown to be intrinsic and independent of the stroma. 26, 35 The post-graft proliferative deficiency found in our study mainly affects the erythroid lineage. It includes a deficiency in BFU-E among CD34 ϩ cells and a decreased capacity of CD34 ϩ cells in BFU-E expansion related to impairment of either BFU-E proliferation or erythroid commitment from more primitive stages. This might explain the persistent deficiency of clonogenic erythroid progenitors previously reported after autologous BMT by our group 4 but the molecular events leading to such abnormal commitment remain to be determined. Although the present study does not provide evidence of a decrease in the proportion of CD34 ϩ ckit ϩ cells during the post-graft period, as reported elsewhere, 21 a more detailed analysis of the expression and function of GF receptors on post-graft CD34 ϩ cells including those for IL-3, GM-CSF and SCF would be of great interest. We are therefore investigating the binding ability of labelled early-acting GF to their respective receptors and CD34 ϩ CD38 Ϫ cell responsiveness to increasing doses of these GF.
